Zydus receives tentative approval from USFDA for Diroximel Fumarate DR Capsules
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres
Glenmark released Picture Post Cards on World Vitiligo Day
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Subscribe To Our Newsletter & Stay Updated